Copyright
©The Author(s) 2016.
World J Gastroenterol. Sep 28, 2016; 22(36): 8211-8218
Published online Sep 28, 2016. doi: 10.3748/wjg.v22.i36.8211
Published online Sep 28, 2016. doi: 10.3748/wjg.v22.i36.8211
Figure 1 Management decisions following fecal calprotectin testing.
Proportion of patients for each of the possible management options, A: When the fecal calprotectin (FC) test caused physicians to change the management of their patient (n = 143); B: When the FC test did NOT cause a change in patient management (n = 136).
- Citation: Rosenfeld G, Greenup AJ, Round A, Takach O, Halparin L, Saadeddin A, Ho JK, Lee T, Enns R, Bressler B. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. World J Gastroenterol 2016; 22(36): 8211-8218
- URL: https://www.wjgnet.com/1007-9327/full/v22/i36/8211.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i36.8211